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Abstract
Introduction: In this study we describe a patient with gross deletion containing the BTK and TIMM8A 
genes. Mutations in these genes are responsible for X-linked agammaglobulinemia and Mohr-Tranebjaerg 
syndrome, respectively. X linked agammaglobulinemia is a rare primary immunodeficiency characterized 
by low levels of B lymphocytes and recurrent microbial infections, whereas, Mohr-Tranebjaerg syndrome 
is a progressive neurodegenerative disorder with early onset of sensorineural deafness. 
Material and methods: For neuroimaging, the magnetic resonance imaging and magnetic reso-
nance spectroscopy of the brain were performed. Microarray analysis was performed to establish the 
extent of deletion.
Results: The first clinical symptoms observed in our patient at the age of 6 months were connected 
with primary humoral immunodeficiency, whereas clinical signs of MTS emerged in the third year  
of live. Interestingly, the loss of speech ability was not accompanied by hearing failure. Neuroimaging 
of the brain suggested leukodystrophy. Molecular tests revealed contiguous X-chromosome deletion syn-
drome encompassing BTK (from exons 6 through 19) and TIMM8A genes. The loss of the patient’s DNA 
fragment was accurately localized from 100 601 727 to 100 617 576 bp on chromosome’s loci Xq22.1.
Conclusions: We diagnosed XLA-MTS in the first Polish patient on the basis of particular molecu-
lar methods. We detected neurodegenerative changes in MRI and MR spectroscopy in this patient. Our 
results provide further insight into this rare syndrome.
Key words: neuroimaging, X-linked agammaglobulinemia, Mohr-Tranebjaerg syndrome, Vanishing 
white matter leukodystrophy, BTK, TIMM8A.
(Centr Eur Immunol 2018; 43 (2): 139-147)
Introduction
X-linked agammaglobulinaemia (XLA) is a primary 
immunodeficiency characterised by early-onset (usually 
between six and 12 months of age) bacterial infections, 
marked reduction in all classes of serum immunoglobu-
lins, and almost total absence (less than 1%) of circulat-
ing B cells. The prevalence of XLA is estimated to be 1 in 
190,000 male births or 1 in 379,000 live births [1]; how-
ever, it may vary, depending on racial and ethnic groups, 
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from 3:1,000,000 to 6:1,000,000 males [2]. The BTK gene, 
mutations of which are responsible for XLA, is located at 
Xq21.3–Xq22, contains 19 exons, and encodes a 659 amino 
acid protein, composed of five different, functional domains 
[3,4]. In the same chromosomal region, located at Xq22.1 
and 770 bp centromerically of the BTK gene, is the TIM-
M8A gene consisting of two exons, formerly named DDP1. 
Protein encoded by these gene functions as a translocase 
and is involved in the import and insertion of hydropho-
bic membrane proteins from the cytoplasm into the mito-
chondrial inner membrane [5,6]. Mutations in the TIMM8A 
gene cause Mohr-Tranebjaerg syndrome/Deafness Dysto-
nia Syndrome (MTS/DDS), characterised by sensorineural 
hearing loss in childhood, followed by adolescent onset of 
progressive dystonia and a variety of non-obligatory neu-
rological features. The prevalence of this rare neurodegen-
erative syndrome is unknown. To date, more than 90 cases 
(37 families) have been described [7-9]. 
According to a database of BTK mutations [http://
databases.lovd.nl/shared/genes/BTK], the majority of dis-
ruptions of this gene are the missense changes (app. 45%), 
frameshifts (app. 32%), and stop changes (app. 17%). The 
gross deletion frequency is 7-8% [10]. Moreover, part of 
these deletions includes the closely located TIMM8A gene, 
and sometimes TAF7L and DRP2 genes. This type of gross 
deletion has been described previously only in 17 patients 
from 14 unrelated families [11-18]. 
In this study, we report the first Polish patient with 
contiguous X-chromosome deletion syndrome including 
the BTK and TIMM8A genes. We present insightful mo-
lecular analysis by multiplex ligation-dependant probe 
amplification (MLPA) method and comparative genomic 
hybridisation (CGH) array, and discuss their utility in the 
diagnostic process. We also present a detailed clinical pic-
ture of an MTS-XLA patient, including abnormal results of 
neuroimaging that has not been described so far. 
Material and methods 
Case presentation 
The patient was the first child born to healthy unrelated 
parents. The family history was affected with epilepsy in 
a cousin and schizophrenia in the grandparents. The fami-
ly history was negative for immunodeficiency and hearing 
loss. The child was healthy at birth and up to five months. 
At five months of age, he was referred to hospital for skin 
abscesses (one on the face and two in the perianal region). 
When he was six months old he developed generalised puru-
lent skin infection with fever and neutropenia (600 cells/μl). 
He subsequently received two antibiotics: Amoxicillin and 
Amikacin. From this time neutropenia appeared only during 
infections. The boy suffered from chronic candidiasis of oral 
mucosa, presumably because of prolonged antibiotic treat-
ment. At seven months of age, he presented with pneumo-
nia, which was treated with three antibiotics (Cefuroxime, 
Clindamycin, and finally Amikacin) with a good clinical 
response. Immunological tests revealed extremely low con-
centrations of serum immunoglobulins: IgG (0,09 g/l), IgA 
(< 0,06 g/l), and IgM (< 0,04 g/l). Flow cytometric analysis 
showed normal percentage and elevated absolute number 
of T cells: CD3-8335 cells/μl (age-matched normal values: 
2500-5000 cells/μl), CD4-4213 cells/μl (age-matched nor-
mal values: 1600-4000 cells/μl), CD8-3847 cells/μl (age-
matched normal values: 560-1700 cells/μl). B lymphocytes 
were absent. Percentage and absolute number of NK cells 
were within the normal range: 733 cells/μ (age-matched nor-
mal values: 170-830 cells/μl). Chemiluminescence was used 
to study the respiratory burst of neutrophils, and it was nor-
mal (the chemiluminescent response of neutrophils occurred 
after stimulation with latex particles).
The patient was referred to the Immunology Unit at 
the Children’s University Hospital in Cracow, where he 
received regular immunoglobulin substitution (intravenous 
and then subcutaneous). From this time, he had no severe 
infections. He was doing well until he was 2.5 years old, 
at which time he suffered from recurrent fevers without 
any other clinical signs of infection. He was treated with 
numerous antibiotics as well as antifungal drugs. At three 
years of age he presented increasing developmental retar-
dation with the loss of speech ability. 
At the age of three the boy was admitted to the hospital 
because of progressive weakness and somnolence. About 
three months earlier his parents stopped immunoglobulin 
substitution. On admission the Division of Paediatrics and 
Developmental Age Neurology, Upper Silesian Child’s 
Health Centre, Katowice, a neurological examination 
revealed: anisocoria, improper positioning of the head – 
tilted to the left side, cerebellar ataxia, wide-based gait, 
and kinetic and intention tremor. The blood tests showed 
a lack of IgA and IgM and very low concentration of IgG. 
The brain MRI revealed generalised cortical and subcortical 
atrophy of the brain and cerebellar hemispheres, areas of 
abnormal signal intensity, and reduced volume of white mat-
ter; there were no contrast enhancement. The MRI picture 
as well as 1H MR spectroscopy suggested leukodystrophy.
After a few months of regular intravenous immunoglob-
ulin substitution, an improvement in neurological status 
was observed. The boy has remained unable to speak, but 
he understands simple commands. He presents behavioural 
abnormalities (irritability). Currently there are no symptoms 
in neurological examination. The patient presents normal 
auditory brainstem response (ABR). Auditory Evoked Po-
tentials (AEP) are also normal. There are no abnormalities 
of middle and external ear with normal tympanogram and 
evoked otoacoustic emissions. The patient did not present 
any marked neurological symptoms probably because of 
his young age. The first symptoms of MTS syndrome may 
appear at different ages (from 18 months to 19 years of age; 
see Table 1). 
Central European Journal of Immunology 2018; 43(2)
Neurodegenerative changes detected by neuroimaging in a patient with contiguous X-chromosome deletion syndrome encompassing 
BTK and TIMM8A genes
141
T
ab
le
 1
. C
lin
ic
al
 f
ea
tu
re
s,
 n
eu
ro
im
ag
in
g,
 a
nd
 d
el
et
io
n 
ch
ar
ac
te
ri
sa
tio
n 
in
 p
at
ie
nt
s 
w
ith
 X
L
A
-M
T
S 
sy
nd
ro
m
e.
 T
he
 p
at
ie
nt
s 
ar
e 
lis
te
d 
ac
co
rd
in
g 
to
 th
e 
tim
e 
of
 p
ub
lic
at
io
n
P
at
ie
nt
/p
at
ie
nt
’s
 
ag
e 
at
 t
he
 d
e-
sc
ri
pt
io
n
(c
ou
nt
ry
)
F
ir
st
  
sy
m
pt
om
es
  
of
 im
m
un
o d
ef
ic
ie
nc
y
A
ge
 a
t 
X
L
A
 
di
ag
no
si
s
A
ge
 w
he
n 
IV
Ig
 
w
er
e 
st
ar
te
d
F
ir
st
 s
ym
pt
om
es
 o
f 
M
T
S 
sy
nd
ro
m
e
D
ys
to
ni
a
A
dd
it
io
na
l c
lin
ic
al
 
sy
m
pt
om
s/
ot
he
r 
co
m
m
en
ts
Si
ze
 o
f 
th
e 
de
le
ti
on
C
N
S 
im
ag
in
g
R
ef
er
en
ce
P
1/
9 
ye
ar
s
(N
or
w
ay
)
12
 m
ot
hs
  
re
cc
ur
en
t i
nf
ec
tio
ns
N
o 
da
ta
N
a 
da
ta
2 
ye
ar
s 
– 
pr
og
re
ss
iv
e 
se
ns
i-
ne
ur
on
al
 d
ea
fn
es
s
5 
ye
ar
s 
– 
ra
pi
dl
y 
pr
og
re
ss
in
g 
dy
st
on
ia
N
a 
da
ta
B
T
K
 (
fr
om
  
in
tr
on
 1
0-
11
) 
– 
T
IM
M
8A
N
o 
da
ta
Ji
n 
et
 a
l.,
 
19
96
P
2/
4.
5 
ye
ar
s
(C
ro
at
ia
)
10
 m
ot
hs
 (
P
se
ud
om
on
as
 
ae
ru
gi
no
sa
 s
ep
si
s)
10
 m
on
th
s
10
 m
on
th
s
3-
4 
ye
ar
s 
– 
he
ar
in
g 
lo
ss
N
o 
da
ta
P
sy
ch
om
ot
or
 d
ev
el
op
-
m
en
t a
nd
 n
eu
ro
lo
gi
c 
ex
am
in
at
io
n 
w
er
e 
no
rm
al
B
T
K
 (
fr
om
  
in
tr
on
 5
-6
) 
– 
T
IM
M
8A
N
o 
da
ta
R
ic
ht
er
  
et
 a
l.,
 2
00
1
P
3/
7.
5 
ye
ar
s
(C
ro
at
ia
)
8 
m
on
th
s 
(s
ev
er
e 
pn
eu
m
o-
co
cc
al
 r
es
pi
ra
to
ry
 in
fe
ct
io
n)
2 
ye
ar
s
2 
ye
ar
s
3-
4 
ye
ar
s 
– 
sp
ec
h 
im
pa
ir
-
m
en
t
4-
7 
ye
ar
s 
– 
ce
nt
ra
l h
ea
ri
ng
 
fa
ilu
re
N
o 
da
ta
P
sy
ch
om
ot
or
 d
ev
el
op
o-
m
en
t w
as
 n
or
m
al
B
T
K
 (
fr
om
  
in
tr
on
 1
8-
19
) 
– 
T
IM
M
8A
1
N
o 
da
ta
R
ic
ht
er
  
et
 a
l.,
 2
00
1
P
4/
14
 y
ea
rs
(L
eb
an
on
)
18
 m
on
th
s 
(r
ec
ur
re
nt
 u
pp
er
 
an
d 
lo
w
er
 r
es
pi
ra
to
ry
 tr
ac
t 
in
fe
ct
io
ns
)
30
 m
on
th
s
30
 m
on
th
s
30
 m
on
th
s 
– 
de
la
ye
d 
sp
ee
ch
 
9 
ye
ar
s 
– 
m
ild
 h
ea
ri
ng
 lo
ss
N
o 
da
ta
11
 y
ea
rs
 –
 e
pi
so
de
s 
 
of
 a
ng
er
 f
ru
st
ra
tio
n,
  
at
te
nt
io
n 
de
fi
ci
t d
is
or
de
r,
 
le
ar
ni
ng
 d
is
ab
ili
tie
s,
 
vi
su
al
 p
ro
ce
ss
in
g 
de
fe
ct
B
T
K
 (
fr
om
  
in
tr
on
 1
8-
19
) 
– 
T
IM
M
8A
N
o 
da
ta
R
ic
ht
er
  
et
 a
l.,
 2
00
1
P
5/
24
 y
ea
rs
(I
ta
ly
)
2 
ye
ar
s 
– 
re
cu
rr
en
t i
nf
ec
tio
ns
 
2 
ye
ar
s
N
ot
 
sp
ec
if
y
2 
ye
ar
s 
– 
bi
la
te
ra
l h
ea
ri
ng
 
lo
ss
15
 y
ea
rs
 –
 p
ro
gr
es
si
ve
 v
is
ua
l 
lo
ss
 
19
 y
ea
rs
 –
 th
e 
pa
tie
nt
 b
eg
an
 
to
 c
om
pl
ai
n 
of
 w
ri
tin
g 
di
ff
ic
ul
tie
s 
th
at
 p
ro
gr
es
si
ve
ly
 
w
or
se
ne
d
19
 y
ea
rs
 –
 d
ys
-
to
ni
c 
po
st
ur
in
g 
of
 th
e 
ri
gh
t u
pp
er
 
lim
b
P
sy
ch
om
et
ri
c 
te
st
in
g 
sh
ow
ed
 a
 m
ild
 d
ef
ic
it 
in
 in
te
lle
ct
ua
l f
un
c-
tio
ni
ng
B
T
K
 (
at
 le
as
t f
ro
m
 
ex
on
 1
9)
 –
 T
IM
M
8A
M
R
I 
of
 th
e 
br
ai
n 
an
d 
ce
rv
ic
al
 
sp
in
e 
w
as
 
no
rm
al
P
iz
zu
ti 
 
et
 a
l.,
 2
00
4
P
6/
33
 y
ea
rs
(C
ze
ch
 R
ep
ub
lic
)
2 
ye
ar
s 
(r
ec
ur
re
nt
 r
es
pi
ra
to
ry
 
in
fe
ct
io
ns
)
9 
ye
ar
s
18
 y
ea
rs
F
ro
m
 2
 to
 5
 y
ea
rs
 o
f 
ag
e-
gr
ad
ua
lly
 w
or
se
d 
de
af
ne
ss
, n
ow
: p
ro
gr
es
si
ve
 
de
af
ne
ss
, a
bn
or
m
al
 s
pe
ec
h,
 
ag
gr
es
si
ve
 b
eh
av
io
ur
, m
us
-
cl
e 
w
as
tin
g
N
o 
da
ta
N
o 
da
ta
B
T
K
 (
fr
om
 e
xo
n 
19
) 
– 
T
IM
M
8A
N
o 
da
ta
S
ed
iv
a 
 
et
 a
l.,
 2
00
7
P
7,
 b
ro
th
er
 o
f 
pa
tie
nt
 P
6/
25
 
ye
ar
s
(C
ze
ch
 R
ep
ub
lic
)
15
 m
on
th
s 
 
(c
om
pl
ic
at
ed
 s
in
us
iti
s)
18
 m
on
th
s
11
 y
ea
rs
S
im
ila
r 
hi
st
or
y 
as
 h
is
 b
ro
th
er
 
(P
at
ie
nt
 6
);
 p
ro
gr
es
si
ve
 
de
af
ne
ss
 s
in
ce
 a
tte
nd
in
g 
pr
es
ch
oo
l
N
o 
da
ta
L
es
s 
pr
on
ou
nc
ed
 p
sy
-
ch
ol
og
ic
al
 c
om
po
ne
nt
 
an
d 
ge
ne
ra
l w
as
tin
g
B
T
K
 (
fr
om
 e
xo
n 
19
) 
– 
T
IM
M
8A
N
o 
da
ta
S
ed
iv
a 
 
et
 a
l.,
 2
00
7
Central European Journal of Immunology 2018; 43(2)
Anna Szaflarska et al.
142
P
at
ie
nt
/p
at
ie
nt
’s
 
ag
e 
at
 t
he
 d
e-
sc
ri
pt
io
n
(c
ou
nt
ry
)
F
ir
st
  
sy
m
pt
om
es
  
of
 im
m
un
o d
ef
ic
ie
nc
y
A
ge
 a
t 
X
L
A
 
di
ag
no
si
s
A
ge
 w
he
n 
IV
Ig
 
w
er
e 
st
ar
te
d
F
ir
st
 s
ym
pt
om
es
 o
f 
M
T
S 
sy
nd
ro
m
e
D
ys
to
ni
a
A
dd
it
io
na
l c
lin
ic
al
 
sy
m
pt
om
s/
ot
he
r 
co
m
m
en
ts
Si
ze
 o
f 
th
e 
de
le
ti
on
C
N
S 
im
ag
in
g
R
ef
er
en
ce
P
8/
di
ed
 a
t t
he
 a
ge
 
of
 6
 y
ea
rs
(C
ze
ch
 R
ep
ub
lic
)
6 
m
on
th
s 
(b
ro
nc
hi
tis
)
2 
ye
ar
s
20
 m
on
th
s
4 
ye
ar
s 
– 
de
la
ye
d 
sp
ee
ch
 
de
ve
lo
pm
en
t l
ed
 to
  
th
e 
di
sc
ov
er
y 
of
 s
en
so
ri
ne
u-
ra
l d
ea
fn
es
s
F
ir
st
 s
ig
ns
 
ap
pe
ar
ed
 a
t t
he
 
ag
e 
of
 5
 y
ea
rs
 
an
d 
pr
og
er
ss
ed
 
ra
pi
dl
y 
to
 
a 
se
ve
re
 f
or
m
 o
f 
sp
as
tic
ity
 u
nt
il 
hi
s 
de
at
h 
du
e 
to
 
pn
eu
m
on
iti
s 
an
d 
ca
rd
io
re
sp
ir
at
or
y 
fa
ilu
re
D
ie
d 
at
 th
e 
ag
e 
 
of
 6
 y
ea
rs
 f
ro
m
  
pr
og
re
ss
iv
e 
dy
st
on
ia
, 
ne
ur
ol
og
ic
al
 im
pa
ir
-
m
en
t a
nd
 g
en
er
al
 
w
as
tin
g
B
T
K
 (
fr
om
  
ex
on
 1
9)
 –
 T
IM
M
8A
N
o 
da
ta
S
ed
iv
a 
 
et
 a
l.,
 2
00
7
P
9/
6 
ye
ar
s
(E
st
on
ia
)
3 
m
on
th
s
(r
ec
ur
re
nt
 r
es
pi
ra
to
ry
  
in
fe
ct
io
ns
).
7 
m
on
th
s
8 
m
on
th
s
S
ub
se
qu
en
tly
 d
ev
el
op
ed
 
sl
ow
ly
 p
ro
gr
es
si
ng
 p
sy
ch
o-
m
ot
or
 r
et
ar
da
tio
n 
an
d 
se
ve
re
 
sp
ee
ch
 im
pa
ir
m
en
t;
4 
ye
ar
s 
– 
se
ns
or
in
eu
ra
l 
he
ar
in
g 
lo
ss
N
o 
da
ta
N
o 
sp
as
tic
ity
 h
as
 b
ee
n 
do
cu
m
en
te
d
B
T
K
 (
fr
om
  
ex
on
 6
) 
– 
T
IM
M
8A
 
N
o 
da
ta
S
ed
iv
a 
 
et
 a
l.,
 2
00
7
P
10
, b
ro
th
er
 o
f 
P
at
ie
nt
 9
/5
 y
ea
rs
(E
st
on
ia
)
A
cu
te
 b
ro
nc
ho
pn
eu
m
on
ia
 
at
 th
e 
ag
e 
of
 7
 m
on
th
s 
an
d 
ch
ro
ni
c 
br
on
ch
iti
s 
si
nc
e 
 
16
 m
on
th
s 
of
 a
ge
2 
m
on
th
s
6 
m
on
th
s
2.
5 
ye
ar
s 
– 
sp
ee
ch
 d
ev
el
op
-
m
en
t h
as
 b
ee
n 
de
la
ye
d 
an
d 
si
gn
s 
of
 h
ea
ri
ng
 lo
ss
 c
ou
ld
 
be
 d
em
on
st
ra
te
d
N
o 
da
ta
N
o 
da
ta
B
TK
 (f
ro
m
  
ex
on
 6
) –
 T
IM
M
8A
N
o 
da
ta
S
ed
iv
a 
 
et
 a
l.,
 2
00
7
P
11
/1
3 
ye
ar
s
(U
S
A
)
A
t 6
 m
on
th
s 
of
 a
ge
 w
ith
 
re
sp
ir
at
or
y 
di
st
re
ss
,  
pn
eu
m
on
ia
, a
nd
 n
eu
tr
op
en
ia
 
th
at
 h
ad
 r
es
ol
ve
d 
by
 th
e 
tim
e 
of
 d
is
ch
ar
ge
8 
m
on
th
s
8 
m
on
th
s
3 
ye
ar
s 
– 
pr
og
re
ss
iv
e 
se
ns
or
in
eu
ra
l h
ea
ri
ng
 lo
ss
, 
de
la
y 
in
 la
ng
ua
ge
 a
nd
 m
ot
or
 
de
ve
lo
pm
en
t
N
o 
da
ta
N
o 
ot
he
r 
nu
er
ol
og
ic
al
 
de
fi
ci
ts
B
TK
 –
 T
IM
M
8A
 –
 
T
A
F
7L
 –
 D
R
P
2
N
o 
da
ta
S
ed
iv
a 
 
et
 a
l.,
 2
00
7
P
12
/8
 y
ea
rs
(U
S
A
)
R
ec
ur
re
nt
 e
pi
so
de
s 
of
 a
cu
te
 
ot
iti
s 
m
ed
ia
 b
eg
in
ni
ng
at
 4
 m
on
th
s 
of
 a
ge
,  
a 
cu
ta
ne
ou
s 
st
ap
hy
lo
co
cc
us
 
in
fe
ct
io
n
5 
ye
ar
s
N
ot
 
sp
ec
if
y
2 
ye
ar
s 
– 
re
ce
pt
iv
e 
an
d 
 
ex
pr
es
si
ve
 la
ng
ua
ge
 d
el
ay
;
3.
5 
ye
ar
s 
– 
se
ve
re
 s
en
so
ri
-
ne
ur
al
 h
ea
ri
ng
 lo
ss
N
o 
da
ta
N
eu
ro
ps
yc
ho
lo
gi
ca
l 
in
ve
st
ig
at
io
n 
de
m
on
-
st
ra
te
d 
no
rm
al
 d
ev
el
-
op
m
en
ta
l m
ile
st
on
es
 
ot
he
r 
th
an
 s
pe
ec
h 
an
d 
la
ng
ua
ge
 
B
T
K
 (
fr
om
  
ex
on
 1
7)
 –
 T
IM
M
8A
  
(e
xo
n 
1)
C
T
 o
f 
th
e 
he
ad
 a
nd
 
op
ht
ha
l-
m
ol
og
ic
 
ex
am
in
a-
tio
n 
w
er
e 
no
rm
al
B
ro
ok
es
  
et
 a
l.,
 2
00
8
P
13
/6
 y
ea
rs
(U
kr
ai
ne
)
5-
6 
m
on
th
s 
(b
ac
te
ri
al
  
pn
eu
m
on
ia
)
4 
ye
ar
s
4 
ye
ar
s
2-
3 
ye
ar
s 
– 
se
ve
re
 s
pe
ec
h 
de
la
y 
N
o 
da
ta
N
o 
ot
he
r 
nu
er
ol
og
ic
al
 
de
fi
ci
ts
B
TK
 (f
ro
m
  
ex
on
 3
) 
– 
T
IM
M
8A
 
– 
T
A
F
7L
 –
 D
R
P
2
N
o 
da
ta
Jy
on
ou
ch
i 
et
 a
l.,
 2
00
8
T
ab
le
 1
. C
on
t.
Central European Journal of Immunology 2018; 43(2)
Neurodegenerative changes detected by neuroimaging in a patient with contiguous X-chromosome deletion syndrome encompassing 
BTK and TIMM8A genes
143
T
ab
le
 1
. C
on
t.
P
at
ie
nt
/p
at
ie
nt
’s
 
ag
e 
at
 t
he
 d
e-
sc
ri
pt
io
n
(c
ou
nt
ry
)
F
ir
st
  
sy
m
pt
om
es
  
of
 im
m
un
o d
ef
ic
ie
nc
y
A
ge
 a
t 
X
L
A
 
di
ag
no
si
s
A
ge
 w
he
n 
IV
Ig
 
w
er
e 
st
ar
te
d
F
ir
st
 s
ym
pt
om
es
 o
f 
M
T
S 
sy
nd
ro
m
e
D
ys
to
ni
a
A
dd
it
io
na
l c
lin
ic
al
 
sy
m
pt
om
s/
ot
he
r 
co
m
m
en
ts
Si
ze
 o
f 
th
e 
de
le
ti
on
C
N
S 
im
ag
in
g
R
ef
er
en
ce
P
14
, b
ro
th
er
 o
f 
pa
tie
nt
 P
13
/6
 
ye
ar
s 
(U
kr
ai
ne
)
5-
6 
m
on
th
s
(b
ac
te
ri
al
 p
ne
um
on
ia
)
4 
ye
ar
s
4 
ye
ar
s
2-
3 
ye
ar
s 
– 
se
ve
re
 s
pe
ec
h 
de
la
y 
N
o 
da
ta
N
o 
ot
he
r 
nu
er
ol
og
ic
al
 
de
fi
ci
ts
B
TK
 (f
ro
m
 e
xo
n 
3)
 
–T
IM
M
8A
 –
 T
A
F
7L
 
– 
D
R
P
2
N
o 
da
ta
Jy
on
ou
ch
i 
et
 a
l.,
 2
00
8
P
15
/1
5 
ye
ar
s
(J
ap
an
es
e)
7 
ye
ar
s
(r
ec
ur
re
nt
 b
ac
te
ri
al
  
in
fe
ct
io
ns
)
7 
ye
ar
s
N
ot
 
sp
ec
if
y
6 
ye
ar
s 
– 
gr
ad
ua
lly
 w
or
se
d 
de
af
ne
ss
N
o 
da
ta
H
ea
ri
ng
 lo
ss
es
 a
re
 
se
ve
re
 a
nd
 p
ro
gr
es
si
ve
B
T
K
 (
fr
om
 e
xo
n 
16
) 
– 
T
IM
M
8A
N
o 
da
ta
A
ra
i e
t a
l.,
 
20
11
P
16
/1
0 
ye
ar
s
(J
ap
an
es
e)
12
 m
on
th
s
(r
ec
ur
re
nt
 o
tit
is
 m
ed
ia
  
an
d 
si
nu
si
tis
)
8 
ye
ar
s
N
ot
 
sp
ec
if
y
18
 m
on
th
s 
– 
de
af
ne
ss
  
an
d 
au
tis
m
N
o 
da
ta
H
ea
ri
ng
 lo
ss
es
 a
re
 
se
ve
re
 a
nd
 p
ro
gr
es
si
ve
B
T
K
 (
fr
om
 e
xo
n 
6)
 
– 
T
IM
M
8A
 –
 T
A
F
7L
 
– 
D
R
P
2
N
o 
da
ta
A
ra
i T
  
et
 a
l.,
 2
01
1
P
17
/2
7 
ye
ar
s 
(F
re
nc
h 
C
an
ad
ia
n)
 
11
 m
on
th
s
11
 m
on
th
s
11
 m
on
th
s
D
ec
re
as
in
g 
vi
su
al
 a
cu
ity
;
2 
ye
ar
s 
– 
se
ve
re
 b
ila
te
ra
l 
he
ar
in
g 
lo
ss
S
eq
ue
la
e 
in
cl
ud
ed
 s
pa
st
ic
 
lo
w
er
 e
xt
re
m
ity
 
pa
ra
pl
eg
ia
 
20
 y
ea
rs
 –
 m
et
as
ta
tic
 
te
st
ic
ul
ar
 s
em
in
o-
m
a 
pr
es
en
te
d 
w
ith
 
te
st
ic
ul
ar
 s
w
el
lin
g 
an
d 
en
la
rg
ed
 p
ar
a-
 a
or
tic
 
no
de
s 
w
er
e 
id
en
tif
ie
d
B
T
K
 –
 T
IM
M
8A
 –
 
T
A
F
7L
N
o 
da
ta
S
ha
ke
r 
 
et
 a
l.,
 2
01
6
Molecular analysis
Informed consent for genetic analysis was obtained 
from the patient’s parents. 
DNA isolation
Genomic DNA was isolated using QIAmp DNA Mini 
Kit (Qiagen, Hilden, Germany) from peripheral blood 
drawn into EDTA. DNA concentrations and quality were 
measured using a Quawell Q5000 UV-Vis spectrophotom-
eter. 
BTK and TIMM8A gene amplification
All exons of BTK  gene (reference sequence: 
ENSG00000010671) and exons and intron of TIMM8A 
gene (reference sequences: ENSG00000126953) were am-
plified by PCR method. Reactions were performed using 
100 ng spectrophotometrically quantified DNA, 0.3 units 
of AmpliTaq Gold polymerase (Thermo Fisher Scientif-
ic, Waltham, MA USA), 0.5 mM of each dNTP, 2.5 mM 
MgCl
2
, and 0.5 μM of each specific primers (Genomed, 
Poland). The reaction volume was 20 μl. Primer sequences 
are available on request. 
Multiplex ligation-dependant probe amplification 
(MLPA)
To detect deletions/duplications of one or more exons 
of the BTK gene, MLPA analysis was performed using 
SALSA MLPA P210 BTK probemix (MRC-Holland, Am-
sterdam, The Netherlands) according to the manufactur-
er’s instructions. Briefly, DNA was denaturated at 98oC for 
5 min and hybridized for at least 12 h at 60oC with a probe 
containing oligonucleotides to analyse all 19 exons of 
BTK gene. Next, 32 ml Ligase-65 master mix was added 
to each reaction and then incubated at 54oC followed by 
5 min at 98oC to deactivate the enzyme. Finally, PCR was 
performed on 10 ml of the ligation product with FAM- 
labelled primers. For fragment analysis, 0.7 μl PCR prod-
ucts, 0.3 μl GeneScan –500 ROX internal size standard, 
and 9 μl formamide (Thermo Fisher Scientific, Waltham, 
MA USA) were run on an ABI Prism 3500 Genetic anal-
yser (Applied Biosystems, Foster city, CA, USA). The 
obtained data were interpreted on the base of the copy 
number ratios, which were calculated by dividing the nor-
malised mean peak areas of each exon in a sample from the 
patient with the normalised mean peak areas of the same 
exons in a sample from healthy control subjects. The data 
were analysed using Coffalyser software (MRC-Holland). 
Microarray analysis
The Agilent SurePrint G3 CGH ISCA v2 Microarray 
Kit 8x60K array platform was used for a comprehensive 
exploration of the patient’s genomic profile and careful 
evaluation of genome abnormalities (Agilent Technolo-
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gies, Santa Clara, CA). The study was performed accord-
ing to the manufacturer’s instruction with additional en-
zymatic digestion. 350 ng of previously isolated patient’s 
genome DNA was used. The first step was digestion of the 
patient’s and reference DNA (Agilent Technologies, Santa 
Clara, CA) simultaneously with RsaI and AluI enzymes 
for 2 h at 37ºC. Next, digested samples were attached with 
random primers and were labelled for 2 h by using appro-
priately cyanine 5 (Cy5) for patient’s DNA and cyanine 3 
(Cy3) for control DNA. An excess amount of fluorescence 
dyes was removed with purification columns (Agilent 
Technologies, Santa Clara, CA). The last step was 24 h 
hybridisation performed at 67°C with a rotation speed of 
20 rpm. The microarray results and a graphical overview 
were obtained using the CytoGenomics software, edition 
v2.9.2.4; (Agilent Technologies, Santa Clara, CA). 
Results 
Molecular analysis
Initial diagnosis of XLA in our patient was suggest-
ed by the very low level of serum immunoglobulins and 
absence of B cells, while the definitive diagnosis was es-
Fig. 1. A) Multiplex ligation-dependant probe amplification analysis of BTK gene in patient (ii) and patient’s mother (i). 
B) Array comparative genomic hybridisation analysis of the X-chromosome of our patient (gene view – TIMM8A and 
BTK genes deletions; cytoband – affected chromosome’s loci Xq22.1; chromosome view – affected chromosome X). 
C) Complete deletion of both exons of TIMM8A confirmed with PCR reaction and electrophoresis. D) Scheme of detected 
TIMM8A and BTK gene deletions
A C
D
B
i)
ii)
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tablished by detecting large deletions involving the BTK 
gene. Initial attempts of sequencing BTK gene revealed 
normal sequences of exons 2 to 5, but PCR reaction failed 
to amplify exons 6 through 19. To verify this observation, 
MLPA analysis was performed. As a result, an almost 
total reduction of the area of the peaks corresponding to 
exons 6-19 was observed (Fig. 1A.ii). MLPA analysis of 
BTK gene in the patient’s mother was also performed in 
order to determine the inheritance of the detected variant; 
however, no deletions were found (Fig. 1A.i). After the 
onset of neurological symptoms, further molecular tests 
were performed. Molecular diagnosis of MTS was based 
on microarray analysis. The aCGH analysis established 16 
kb deletion including BTK and TIMM8A gene (Fig. 1B). 
The loss of the patient’s DNA fragment was accurately 
localised from 100 601 727 to 100 617 576 bp. Complete 
deletion of both exons of TIMM8A but no intron situated 
proximately was confirmed using PCR reaction (Fig. 1C). 
The scheme of detected BTK and TIMM8A genes deletion 
was presented on Figure 1D. 
Neuroimaging
MRI images showed dilated lateral ventricle and, to 
a lesser extent, subarachnoid spaces, which means severe 
atrophy. Apart from that, there were extensive, multifocal, 
but not diffuse white matter abnormalities. The FLAIR im-
ages showed no tissue rarefaction or cystic abnormality. 
There was cerebellar atrophy. No enhancement after con-
trast was seen (Fig. 2). MR spectroscopy revealed neurons 
as well as myelin damage, suggesting degenerative process 
and an early stage of vanishing white matter leukodystro-
phy (VHM). However, the MRI images were not compat-
Fig. 2. Magnetic resonance imaging pictures of our patient with XLA-MTS. The images show that the lateral ventricles, 
and to a lesser degree the subarachnoid spaces, are dilated. The third ventricle, aqueduct, and fourth ventricle are enlarged. 
Extensive but not diffused signal abnormalities are seen in the cerebral white matter. The corpus callosum is involved in 
the white matter abnormality. There is cerebellar atrophy. No enhancement after contrast is observed
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ible with diagnosis of VHM because severe atrophy is not 
typical for primary white matter diseases. Such a picture 
suggested instead a primary neuronal disease. The partial 
regression of disseminated changes in the supratentorial 
white matter after four months also denies VHM. MRI 
changes have not been observed so far in MTS-XLA pa-
tients. 
Discussion
To date, the simultaneous deletion of at least BTK and 
TIMM8A genes was previously described in 17 patients, 
but none from Poland. Detailed characterisation of all re-
ported cases are shown in Table 1. According to these data, 
all the patients with XLA-MTS presented sensorineural 
deafness. Additionally, patients developed dystonia, visu-
al processing defects, mental retardation, attention deficit 
disorder, learning disabilities, behaviour abnormalities, 
and general wasting. However, these symptoms were ob-
served in different combinations and they are not relat-
ed to the extent of deletion. On the contrary, our patient 
presents normal hearing ability, mild mental retardation, 
behavioural abnormalities (irritability), and no dystonia 
signs. He has no speech ability, but in the past he had been 
able to speak some single words. He had ataxia but only 
for a short period of time, after the long break in immuno-
globulin substitution. 
The data from neuroimaging in pure MTS patients 
published so far revealed unspecific alterations in com-
puterised tomography (CT) scans, such as diffuse, gener-
alised cerebral or cortical atrophy [7, 19]. In two patients 
with this syndrome magnetic resonance imaging (MRI) 
revealed atrophy of the occipital cortex. The results of the 
first PET study performed in a pure MTS patient exhib-
ited hypometabolic areas over parietal, medial temporal, 
and frontal brain areas [20]. Next PET examination was 
described by Binder et al. in 2003 [8]. It revealed a pro-
nounced reduction of metabolism in both occipital lobes, 
including the visual cortex, but also in the basal ganglia 
and both rostral parietal lobes. However, there are very 
few data on neuroimaging in MTS-XLA patients. In one 
patient, CT of the head was normal [15], and in the other, 
MRI of the brain and cervical spine was also normal [13]. 
There are no data of PET examinations in MTS-XLA pa-
tients.
In our study, a genetic basis of the disease was estab-
lished by an array CGH analysis because the MLPA meth-
od was insufficient. The high resolution of aCGH allows 
an indication of changes in copy number variation even of 
a single gene. Therefore, the application of such analysis 
has increased in genetic abnormality diagnostics and was 
used to establish a diagnosis for patients 13 to 17 with 
XLA-MTS (Table 1). That is why we recommend array 
CGH analysis for more accurate diagnosis of gross dele-
tions that comprise more than one gene. 
Conclusions
In conclusion, on the basis of previously described 
cases (Table 1), we suggest that complete deletion of 
TIMM8A and BTK genes is associated with milder clinical 
picture in comparison to classical MTS syndrome. Howev-
er, the observation period of these patients was very short 
(Table 1). Here, for the first time, we have detected neu-
rodegenerative changes in MRI and MR spectroscopy in 
an XLA-MTS patient. We do not know if these findings 
are typical for this disease due to the very small amount 
of data about neuroimaging in XLA-MTS patients. That is 
why a description of each new case would be valuable to 
extend our knowledge about this rare syndrome. 
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